loading...| Preferred Name |
valbenazine |
|
| Synonyms |
valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester |
|
| ID |
http://purl.bioontology.org/ontology/MESH/C000603978 |
|
| altLabel |
valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester Ingrezza NBI-98854 (2R,3R,11BR)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl l-valinate |
|
| cui |
C4473507 C4079899 C4279586 C4078701 |
|
| Has mapping qualifier | ||
| HM |
D013747/Q000031 D014633/Q000031 |
|
| Inverse of RB |
54K37P50KH |
|
| LT |
TRD |
|
| Mapped to | ||
| MDA |
20160103 |
|
| MeSH Frequency |
75 |
|
| MMR |
20191030 |
|
| notation |
C000603978 |
|
| prefLabel |
valbenazine |
|
| SC |
1 |
|
| Scope Statement |
inhibits vesicular monoamine transporter 2 (VMAT2); used to treat tardive dyskinesia; structure in first source |
|
| SRC |
Expert Opin Investig Drugs. 2015 Jun;24(6):737-42. |
|
| TERMUI |
T000893080 T000923864 T000904423 T000893079 T000993860 |
|
| TH |
NLM (2016) NLM (2020) FDA SRS (2017) USAN (19XX) INN (19XX) NLM (2017) |
|
| tui |
T109 T116 T121 |